PHILADELPHIA, PA and KFAR SABA, ISRAEL, July 12, 2015—ControlRad Systems Inc., a medical device company developing innovative products that dramatically reduce damaging radiation exposure to patients and physicians during fluoroscopic procedures, announced today that industry expert Guillaume Bailliard has been named Chief Executive Officer and member of the Board of Directors. Founding CEO, Steven Nichtberger, will remain Chairman of the Board.
“Based on milestones recently achieved with the development of our products and our emerging network of partners, the Board determined that this was the right moment to implement our longstanding plan to hire an industry leader with imaging experience,” said Dr. Nichtberger, Chairman of the Board. “Guillaume is an exceptionally strong leader and industry expert with relevant experience from GE Healthcare as well as early‐stage companies. We are excited to welcome him to ControlRad Systems.”
Mr. Bailliard has held a variety of key leadership roles in both public multi‐national and private innovative companies. As a Mechanical Engineer by training, he started his career designing medical devices at Genzyme Surgical and then transitioned to GE Healthcare in a Leadership Training program. While at GE, Mr. Bailliard held various sales and management positions including in interventional fluoroscopy, ultimately responsible for the Americas X‐Ray Sales operations where he restored double‐digit growth. Mr. Bailliard then joined a privately held company launching an innovative imaging product in the breast cancer market, Naviscan PET Systems, followed with being appointed President of Mauna Kea Technologies Inc. introducing a disruptive imaging technology in gastroenterology, pulmonology and surgery. In these roles, Mr. Bailliard’s efforts were focused on developing go‐to‐market strategies for disruptive technologies, building high performing teams, overcoming barriers to adoption, and growing businesses.
“I am thrilled to join ControlRad Systems at such a pivotal time. While the positive clinical impact of interventional fluoroscopy on patient care is unquestionable, the consequences of long‐term ionizing radiation exposure to patients and medical staff is increasingly recognized as a concern,” said Mr. Bailliard. “ControlRad Systems’ innovative patented products have demonstrated the ability to dramatically reduce radiation exposure without diminishing image quality or workflow.”
ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals. These products are designed to improve safety without compromising image quality or workflow. This is accomplished with an integrated set of proprietary components which optimize the X-ray beam to deliver optimal image quality in the clinically-relevant region of focus of the physician while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Philadelphia and has engineering development facilities in Kfar Saba, Israel. For more information, visit www.controlrad.com.